Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM032 in Patients
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Norroy Bioscience Co., LTD
- Target Recruit Count
- 20
- Registration Number
- NCT06389695
- Locations
- 🇨🇳
Affliated Hospital of Jiangnan University, Wuxi, Jiangsu, China
🇨🇳Peking Union Medical College Hospital, Beijing, China
Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM005 in Patients
Phase 1
Completed
- Conditions
- Clear Cell Renal Cell Carcinoma Metastatic
- Interventions
- Drug: 68Ga-NYM005 injection
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Norroy Bioscience Co., LTD
- Target Recruit Count
- 19
- Registration Number
- NCT06389682
- Locations
- 🇨🇳
Affliated Hospital of Jiangnan University, Wuxi, Jiangsu, China
🇨🇳Peking Union Medical College Hospital, Beijing, China
A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC
Phase 1
Active, not recruiting
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Drug: 177Lu-NYM032 injection
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Norroy Bioscience Co., LTD
- Target Recruit Count
- 30
- Registration Number
- NCT06383052
- Locations
- 🇨🇳
Affliated Hospital of Jiangnan University, Wuxi, China
© Copyright 2025. All Rights Reserved by MedPath